Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 34.50% is 157% above its 4-year average of 13.40%, near the high end of its 4-year range (5.93%–34.50%).
52.69% above its 12-month average of 22.59%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-07-03): 8.50%.
RETURN ON ASSETS (ROA)
34.50%
RETURN ON ASSETS (ROA) AVG TTM
22.59%
RETURN ON ASSETS (ROA) AVG 3Y
17.42%
RETURN ON ASSETS (ROA) AVG 5Y
13.40%
RETURN ON ASSETS (ROA) AVG 10Y
14.96%
RETURN ON ASSETS (ROA) AVG 15Y
3.47%
RETURN ON ASSETS (ROA) AVG 20Y
-9.27%
CURRENT VS TTM AVG
+52.69%
CURRENT VS 3Y AVG
+98.09%
CURRENT VS 5Y AVG
+157.42%
CURRENT VS 10Y AVG
+130.66%
CURRENT VS 15Y AVG
+893.01%
CURRENT VS 20Y AVG
+472.19%
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+206.93%
vs the sector median at left
Exelixis, Inc.
Market Cap
$14.66B
Return on Assets (ROA)
34.50%
TTM Avg
22.59%
3Y Avg
17.42%
5Y Avg
13.40%
Market Cap
$14.69B
Return on Assets (ROA)
-3.17%
TTM Avg
-0.94%
3Y Avg
2.58%
5Y Avg
3.75%
Market Cap
$14.63B
Return on Assets (ROA)
13.16%
TTM Avg
9.75%
3Y Avg
8.43%
5Y Avg
10.25%
Market Cap
$14.54B
Return on Assets (ROA)
8.49%
TTM Avg
0.81%
3Y Avg
0.80%
5Y Avg
0.69%
Market Cap
$15.07B
Return on Assets (ROA)
10.07%
TTM Avg
7.10%
3Y Avg
8.43%
5Y Avg
7.35%
Market Cap
$14.04B
Return on Assets (ROA)
33.29%
TTM Avg
-24.43%
3Y Avg
-40.18%
5Y Avg
-39.80%
Market Cap
$13.81B
Return on Assets (ROA)
-113.81%
TTM Avg
-122.22%
3Y Avg
-139.21%
5Y Avg
-114.33%
Market Cap
$13.11B
Return on Assets (ROA)
-57.20%
TTM Avg
-68.10%
3Y Avg
-82.79%
5Y Avg
-75.08%
Market Cap
$13.01B
Return on Assets (ROA)
16.05%
TTM Avg
17.04%
3Y Avg
15.32%
5Y Avg
20.00%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Exelixis, Inc. (EXEL) | $14.66B | 34.50% | 22.59% | 17.42% | 13.40% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.69B | -3.17% | -0.94% | 2.58% | 3.75% |
| Neurocrine Biosciences, Inc. (NBIX)vs › | $14.63B | 13.16% | 9.75% | 8.43% | 10.25% |
| Jazz Pharmaceuticals plc (JAZZ)vs › | $14.54B | 8.49% | 0.81% | 0.80% | 0.69% |
| Solventum Corporation (SOLV)vs › | $15.07B | 10.07% | 7.10% | 8.43% | 7.35% |
| Ascendis Pharma A/S (ASND)vs › | $14.04B | 33.29% | -24.43% | -40.18% | -39.80% |
| Summit Therapeutics Inc. (SMMT)vs › | $13.81B | -113.81% | -122.22% | -139.21% | -114.33% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.11B | -57.20% | -68.10% | -82.79% | -75.08% |
| Halozyme Therapeutics, Inc. (HALO)vs › | $13.01B | 16.05% | 17.04% | 15.32% | 20.00% |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.93B | 6.18% | 14.27% | 15.75% | 18.01% |
ROA
34.5%
ROE
46.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-01-02 | 27.51% |
| 2025-01-03 | 17.68% |
| 2023-12-31 | 7.06% |
| 2022-12-31 | 5.93% |
| 2021-12-31 | 8.83% |
| 2020-12-31 | 5.23% |
| 2019-12-31 | 17.02% |
| 2018-12-31 | 48.52% |
| 2017-12-31 | 23.54% |
| 2016-12-31 | -11.75% |
| 2015-12-31 | -51.07% |
| 2014-12-31 | -81.88% |
| 2013-12-31 | -48.63% |
| 2012-12-31 | -20.48% |
| 2011-12-31 | 19.25% |
| 2010-12-31 | -25.59% |
| 2009-12-31 | -39.38% |
| 2008-12-31 | -40.55% |
| 2007-12-31 | -20.96% |
| 2006-12-31 | -25.67% |
| 2005-12-31 | -25.37% |
| 2004-12-31 | -47.11% |
| 2003-12-31 | -26.49% |
| 2002-12-31 | -25.40% |
| 2001-12-31 | -20.54% |
| 2000-12-31 | -36.75% |
| 1999-12-31 | -98.94% |
| 1998-12-31 | -174.43% |
